Big Data will have an impact on health and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases. HARMONY: Ready to collect data and deliver outcomes.
During the 23rd Congress of European Hematology Association (EHA23) we had the opportunity to present the HARMONY Alliance and its activities to the Congress participants. We hope many of 11.700 professionals picked up information fitting their specific interest.
We are looking back at a very successfull session, press briefing and exhibition.
The HARMONY Session was attend by approx 350 participants: Clinicians, Researchers, Data Providers, Patient and Nurses’ organizations, and additional interested professionals. We explained the impact big data will have in the future and who will benefit. In addition we updated our audience on HARMONY’s latest steps and achievements.
The following HARMONY Partners shared their vision and project progress: Guillermo Sanz, HARMONY Co-Chair, HULAFE, Spain; Pam Bacon, HARMONY Project Co-Leader, CELGENE, Switzerland; Michel van Speybroeck, Janssen, Belgium & Work Package 3 Lead; Ana Heredia, GMV, Spain & Work Package 3 Lead; John Butler, WP8 Lead, Bayer, Germany; Lars Bullinger, WP2 Lead, Charité, Germany; Aliki Taylor, Takeda, United Kingdom; Harmut Döhner, UULM, Germany; Estella Mendelson, Novartis, USA; Lesley Ann Sutton, European research Initiative on CLL, Italy; Pieter Sonneveld, ErasmusMC, The Nederlands; Bruno Costa, Celgene, Switzerland; Francesco Lo Coco, University of Rome Tor Vergata, Italy; Jesús María Hernández, HARMONY Co-ordinator, IBSAL, Spain; Mirko Vukcevic, HARMONY Project Leader, Novartis, Switzerland.
|
|
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
.jpg)
.jpg)
.jpg)
.jpg)
